key: cord-0253568-gxba3qem authors: Liu, Jianying; Liu, Yang; Xia, Hongjie; Zou, Jing; Weaver, Scott C.; Swanson, Kena A.; Cai, Hui; Cutler, Mark; Cooper, David; Muik, Alexander; Jansen, Kathrin U.; Sahin, Ugur; Xie, Xuping; Dormitzer, Philip R.; Shi, Pei-Yong title: BNT162b2-Elicited Neutralization of Delta Plus, Lambda, and Other Variants date: 2021-09-14 journal: bioRxiv DOI: 10.1101/2021.09.13.460163 sha: 3829509cd3f6ffb291c39402140e02897dd48dac doc_id: 253568 cord_uid: gxba3qem BNT162b2-elicited human sera are known to neutralize the currently dominant Delta SARS-CoV-2 variant. Here, we report the ability of 20 human sera, drawn 2 or 4 weeks after two doses of BNT162b2, to neutralize USA-WA1/2020 SARS-CoV-2 bearing variant spikes from Delta plus (Delta-AY.1, Delta-AY.2), Delta-Δ144 (Delta with the Y144 deletion of the Alpha variant), Lambda, and B. 1.1.519 lineage viruses. Geometric mean plaque reduction neutralization titers against Delta-AY.1, Delta-AY.2, and Delta-Δ144 viruses are slightly lower than against USA-WA1/2020, but all sera neutralize the variant viruses to titers of ≥80. Neutralization titers against Lambda and B. 1.1.519 variants and against USA-WA1/2020 are equivalent. The susceptibility of Delta plus, Lambda, and other variants to neutralization by the sera indicates that antigenic change has not led to virus escape from vaccine-elicited neutralizing antibodies and supports ongoing mass immunization with BNT162b2 to control the variants and to minimize the emergence of new variants. As of August 13, 2021, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused over 205 million infections and more than 4.3 million deaths due to coronavirus disease 2019 (COVID-19; https://coronavirus.jhu.edu/). Since its emergence in late 2019, SARS-CoV-2 has accumulated mutations, leading to variants with higher transmission, more efficient replication, and potentially immune evasion. 1-5 Many of these mutations have occurred in the viral spike glycoprotein, which is responsible for binding to the host receptor, angiotensinconverting enzyme 2 (ACE2), during virus entry. Based on the effects of mutations on viral transmission, disease severity, and clinical diagnosis, the World Health Organization (WHO) has categorized SARS-CoV-2 strains into "variants of concern (VOC)," "variants of interest (VOI)," and "variants of alert (VOA)" (https://www.who.int/en/activities/tracking-SARS-CoV-2- As the pandemic continues, it is critical to monitor closely the new variants for their transmission, pathogenesis, and potential escape from vaccines and therapeutics. BNT162b2 is an mRNA vaccine expressing the full-length prefusion spike glycoprotein of SARS-CoV-2, stabilized in the prefusion conformation. 6 BNT162b2 has recently been approved for vaccination of individuals 16 We aimed to study the impact of antigenic variation in the SARS-CoV-2 spike glycoprotein on neutralization by antibodies elicited by the wild type (WT) spike glycoprotein encoded by BNT162b2 RNA. Therefore, we used a reverse genetic system to generate a panel of SARS-CoV-2 with a USA-WA1/2020 genetic background (a viral strain isolated in January 2020 and defined as WT) and spike glycoproteins from the newly emerged variants (Extended data Fig. 1a) . Sequencing of viral stocks confirmed that there were no undesired mutations in the spike gene. We compared the neutralization susceptibility of the chimeric variant SARS-CoV-2s to a panel of 20 sera collected from BTN162b2-immunized human participants in the pivotal clinical trial. 6, 15 As reported previously, the serum specimens were drawn 2 or 4 weeks after two immunizations with 30 μg of BNT162b2, spaced three weeks apart. 9 ,10 Each serum was tested simultaneously for its 50% plaque reduction neutralizing titers (PRNT 50 ) against the WT and chimeric variant viruses (Extended Data Table 1 ). All the sera neutralized the WT and all the mutant viruses with titers of 1:80 or higher (Fig. 1) immune sera efficiently neutralized all tested viruses. We have taken a systematic approach to measuring BNT162b2-elicted neutralization of newly emerged variants. We use a reverse genetic system to generate chimeric SARS- improved replication fitness through mutation P681R-enhanced protease cleavage of the fulllength spike to S1 and S2 subunits, as one mechanism leading to increased viral infection. 18, 19 Viral RNA loads in the oropharynx from Delta variant-infected patients were over 1,000-fold higher than those from the original Wuhan virus-infected individuals. 20 Collectively, the results suggest that improved viral fitness due to more efficient furin cleavage, rather than immune escape, may account for breakthrough infections of the Delta variant in vaccinated people. More efficient furin cleavage of the influenza fusion protein, hemagglutinin, increases the viral pathogenicity to an even greater extent. 21 One limitation of this study is the potential for mutations to alter neutralization by affecting spike function rather than antigenicity (e.g., mutation P681R that improves viral variants were engineered into infectious cDNA clones of an early SARS-CoV-2 isolate, USA-WA1/2020, using a standard PCR-based mutagenesis method. 22 The protocol for construction of recombinant SARS-CoV-2 was reported previously. 23 The full-length cDNAs of viral genomes containing the variant spike mutations were assembled by in vitro ligation. The resulting genome-length cDNAs served as templates for in vitro transcription of full-length viral RNAs. The full-length viral RNA transcripts were electroporated into Vero E6 cells. On day 2 post electroporation (when the electroporated cells developed cytopathic effects due to recombinant virus production and replication), the original viral stocks (P0) were harvested from culture medium. The P0 viruses were amplified on Vero E6 cells for another round to produce working viral stocks (P1). The infectious titers of the P1 viruses were quantified by plaque assay on Vero E6 cells. 22 The complete spike genes from the P1 viruses were sequenced to ensure no undesired mutations. The P1 viruses were used for neutralization tests. We quantified the P1 stocks for their genomic RNA content by RT-qPCR and for their infectious titers by plaque assay on Vero E6 cells. The RT-qPCR and plaque assays were performed as previously reported. 1, 23 The ratio of viral RNA to PFU was calculated to indicate the specific infectivity of each virus. BTN162b2-immunized participants in the pivotal clinical trial. 6, 15 The sera were collected 2 or 4 weeks after two doses of 30 μg of BNT162b2 mRNA, spaced 3 weeks apart. As indicated in Extended Data Table 1 , 5 of the 20 participants provided sera at both 2 and 4 weeks after the second dose of vaccine. The ages of human subjects are also presented in Extended Data Table 1 . A PRNT 50 was performed to measure the neutralizing titers of individual serum specimens. A detailed PRNT 50 protocol was reported previously. 24 Individual sera were 2-fold serially diluted in culture medium with a starting dilution of 1:40. One hundred PFUs of WT or chimeric SARS-CoV-2 with variant spike were mixed with the serially diluted sera. After incubation at 37 °C for 1 h, the serum/virus mixtures were inoculated on to 6-well plates with a monolayer of Vero E6 cells (pre-seeded the previous day). The PRNT 50 titer was defined the minimal serum dilution that suppressed >50% of viral plaques. Statistical analysis. Statistical analyses were performed by Graphpad Prism 9 for all experiments as detailed in legends to individual figures. Source data for generating the main figure are available in the online version of the paper. Any other information is available upon request. We thank the participants from Pfizer-BioNTech clinical trial C4591001, who donated the post-vaccination sera. We also thank the colleagues at Pfizer and BioNTech who developed and produced the BNT162b2 vaccine candidate. We thank Qi Yang for analysis of variant sequences. The study was supported by Pfizer and BioNTech. Conceptualization . The values in the graph represent means with 95% confidence intervals. A nonparametric two-tailed Mann-Whitney test was used to determine significant differences between USA-WA1/2020 and variant viruses. P values were adjusted using the Bonferroni correction to account for multiple comparisons. Differences were considered significant if P < 0.05; n.s. means no statistical difference. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo The N501Y spike substitution enhances SARS-CoV-2 transmission. bioRxiv Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine BNT162b vaccines protect rhesus macaques from SARS-CoV-2 BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants Neutralizing Activity of BNT162b2-Elicited Serum BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants & National Study Group for Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization Neutralization of SARS-CoV-2 variants B.1.617.1 and B.1.525 by BNT162b2-elicited sera Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant SARS-CoV-2 B.1.617.2 Delta variant emergence, replication and sensitivity to neutralising antibodies Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant Role of hemagglutinin cleavage for the pathogenicity of influenza virus An Infectious cDNA Clone of SARS-CoV-2 Engineering SARS-CoV-2 using a reverse genetic system The data for USA-WA1/2020 are from two independent experiments. The results for other variants are from one experiment each. For each independent experiment, the individual PRNT 50 value is the geometric mean of duplicate plaque assay results; no differences were observed between the duplicate assays. § GMT: Geometric mean neutralizing titers. ^9 5% CI: 95% confidence interval (95% CI) for the GMT.